6 articles
Catalyst Pharmaceuticals will lose patent protection for FIRDAPSE in February 2035, triggering an expected 70-80% revenue decline as generic manufacturers enter the market. The neuromuscular treatment generated $254 million in 2023, representing most of the Florida-based company's sales.
Quest Diagnostics risks repricing or terminating its Haystack Oncology acquisition if technology validation fails, jeopardizing its entry into the $8B global liquid biopsy market. The U.S. diagnostics giant's strategy mirrors international competitors racing to secure minimal residual disease detection capabilities. Quest carries $2.4B in debt while rivals Guardant Health and Natera dominate current market share.
The biotechnology sector is approaching a rare commercial inflection point as gene therapy, mRNA oncology, and cell therapy programs converge on regulatory milestones across the United States and Europe simultaneously. This pipeline surge is fundamentally altering how the industry attracts capital — shifting the investor calculus from speculative binary bets toward cash-flow-oriented, commercially durable businesses. For global markets, the implications stretch from healthcare access and manufac
The world's leading pharmaceutical companies are accelerating portfolio transformations through acquisitions, regulatory breakthroughs, and revised financial guidance, signalling a new phase of competitive repositioning across global healthcare markets. From Finland's Orion to American and Swiss titans Johnson & Johnson and Roche, the industry is recalibrating for a post-restructuring growth cycle. The moves carry broad implications for healthcare investors, patients, and policymakers worldwide.
Pfizer has confirmed plans to enter the fast-growing global GLP-1 obesity drug market by 2028, following its acquisition of clinical-stage biotech Metsera. The move pits the American pharmaceutical giant against a field dominated by Denmark's Novo Nordisk and US rival Eli Lilly, in a market projected to exceed $130 billion annually by the early 2030s. The deal signals a broader industrywide reckoning with obesity as a defining public health and commercial challenge of the coming decade.
US biotech Jade Biosciences has confirmed plans to initiate a Phase 1 clinical trial for its lead monoclonal antibody candidate, JADE301, by the first quarter of 2027. The move positions the company within a fiercely competitive global autoimmune therapeutics market worth over $100 billion, where European and Asian challengers are increasingly contesting American pharmaceutical dominance. The announcement signals a structured development roadmap as investor scrutiny of clinical-stage biotechs ri